Newly formulated GROWJECT(®) is bioequivalent to the prior GROWJECT(®) formulation and causes less injection-associated pain

Daily treatment with subcutaneous injections of recombinant human GH can be physically and emotionally stressful for children and their caregivers owing to the pain caused by injection. In this study, 52 healthy male subjects were randomized to investigate the bioequivalence and compare the safety a...

Descripción completa

Detalles Bibliográficos
Autores principales: Owada, Yasuko, Asano, Yuuka, Hanada, Takashi, Yasukawa, Hidehito, Yamaoka, Mariko, Mita, Yoko, Namba, Noriyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society for Pediatric Endocrinology 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783130/
https://www.ncbi.nlm.nih.gov/pubmed/33446950
http://dx.doi.org/10.1297/cpe.30.35

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783130/
https://www.ncbi.nlm.nih.gov/pubmed/33446950
http://dx.doi.org/10.1297/cpe.30.35

Ejemplares similares